Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 18/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 18/20 | 0.62 |
| ▸ | OPRK1 | P41145 | 14/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.57 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3585201 | 1.00 | OPRL1 (0.62) | OPRL1OPRM1OPRK1OPRD1OGFRL1 | |
| SCHEMBL3579819 | 0.90 | OPRL1 (0.78) | OPRL1OPRM1OPRK1OPRD1KCNH2 | |
| SCHEMBL3579815 | 0.90 | OPRL1 (0.78) | OPRL1OPRM1OPRK1OPRD1KCNH2 | |
| SCHEMBL13343645 | 0.89 | OPRL1 (0.61) | OPRL1OPRM1OPRK1OPRD1KCNH2 | |
| SCHEMBL4431657 | 0.88 | OPRL1 (0.58) | OPRL1OPRM1OPRK1OPRD1OGFRL1 | |
| SCHEMBL4431660 | 0.88 | OPRL1 (0.58) | OPRL1OPRM1OPRK1OPRD1OGFRL1 | |
| SCHEMBL2238940 | 0.87 | OPRL1 (0.79) | OPRL1OPRM1OPRK1OPRD1OGFRL1 | |
| SCHEMBL2238943 | 0.87 | OPRL1 (0.79) | OPRL1OPRM1OPRK1OPRD1OGFRL1 | |
| SCHEMBL3598292 | 0.86 | OPRL1 (0.58) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL3598296 | 0.86 | OPRL1 (0.58) | OPRL1OPRM1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877779-B2 | Benzimidazole compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-11-04 | — | — | US | disclosed |
| US-20100120841-A1 | BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-05-13 | — | — | US | disclosed |
| EP-2128154-A1 | BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120841-A1 | BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | ORMDL3, OXA1L, OGFRL1 | OPRL1 11/4885OPRM1 55/4885OPRK1 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.